Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
AstraZeneca
Boehringer Ingelheim
Moodys
Johnson and Johnson

Last Updated: January 26, 2023

CLINICAL TRIALS PROFILE FOR ALTACE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Altace

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00044265 ↗ Treatment of Pediatric Hypertension With Altace Trial Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 4 2002-07-01 Ramipril is an ACE inhibitor that has been marketed in the US for the treatment of hypertension since 1991. It has been shown to be effective in reducing both systolic and diastolic blood pressure in adults when used once daily. ACE inhibitors are frequently used to treat hypertension in children, however ramipril has not been extensively tested in children, and information regarding the efficacy and safety would therefore be of benefit to children. This study is designed to demonstrate the efficacy and safety of ramipril in the treatment of hypertension in children ages 6 through 16 years.
NCT00044265 ↗ Treatment of Pediatric Hypertension With Altace Trial Completed Pfizer Phase 4 2002-07-01 Ramipril is an ACE inhibitor that has been marketed in the US for the treatment of hypertension since 1991. It has been shown to be effective in reducing both systolic and diastolic blood pressure in adults when used once daily. ACE inhibitors are frequently used to treat hypertension in children, however ramipril has not been extensively tested in children, and information regarding the efficacy and safety would therefore be of benefit to children. This study is designed to demonstrate the efficacy and safety of ramipril in the treatment of hypertension in children ages 6 through 16 years.
NCT00274599 ↗ PROBE Investigation of the Safety & Efficacy of Telmisartan (MicardisĀ®) vs Ramipril (AltaceĀ®) Using ABPM in HTN Completed Boehringer Ingelheim Phase 4 2002-10-01 Demonstrate that telmisartan 80mg was at least as effective and possibly superior to ramipril 5mg & 10mg in lowering mean ambulatory DBP and SBP during the last 6 hrs of the 24-hr dosing interval in mild-to-moderate hypertensives at the end of 8 and 14 week treatment phases.
NCT00281593 ↗ Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension Completed Boehringer Ingelheim Phase 3 2006-04-01 To identify dose combinations of telmisartan and ramipril that are more effective in reducing diastolic blood pressure than each of the respective monotherapies in patients with Stage I or II hypertension.
NCT00389519 ↗ A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents Terminated Pfizer Phase 3 2006-10-01 The primary purpose of this study is to evaluate the blood pressure lowering effects of ramipril, an FDA-approved drug for the treatment of hypertension in adults, in children and adolescents aged 6 to 16 years with hypertension.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Altace

Condition Name

Condition Name for Altace
Intervention Trials
Hypertension 9
Healthy 7
Metabolic Syndrome 2
Diabetes 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Altace
Intervention Trials
Hypertension 8
Disease 2
Vascular Diseases 2
Metabolic Syndrome X 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Altace

Trials by Country

Trials by Country for Altace
Location Trials
United States 132
Canada 27
India 5
Argentina 2
Poland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Altace
Location Trials
California 7
Illinois 6
Florida 5
Texas 5
Pennsylvania 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Altace

Clinical Trial Phase

Clinical Trial Phase for Altace
Clinical Trial Phase Trials
Phase 4 5
Phase 3 6
Phase 2/Phase 3 1
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Altace
Clinical Trial Phase Trials
Completed 18
Terminated 5
Unknown status 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Altace

Sponsor Name

Sponsor Name for Altace
Sponsor Trials
Teva Pharmaceuticals USA 3
Boehringer Ingelheim 2
Ranbaxy Laboratories Limited 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Altace
Sponsor Trials
Industry 19
Other 18
NIH 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Express Scripts
McKinsey
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.